Today, another Creating Hope Act pediatric priority review voucher sold for $245M!
This voucher was sold to Sanofi by Retrophin. FDA had awarded Retrophin the voucher upon approval of Cholbam for bile acid synthesis disorders.
These eye popping valuations for Creating Hope Act vouchers are sure to encourage companies to develop drugs for kids with cancer and other rare diseases.
Our next goals are to advocate for the reauthorization of the Creating Hope Act and the Kids Innovative Drugs Initiative which would require companies to undertake pediatric studies for cancer drugs just as they do for drugs for other diseases.
Thank you to the 170 pediatric cancer organizations, children’s hospitals and cancer hospitals that have endorsed these initiatives. And thank you for your support.
Email Blast: pdf